Indacaterol
- Generic Name
- Indacaterol
- Brand Names
- Hirobriz, Onbrez, Ultibro, Oslif Breezhaler, Hirobriz Breezhaler, Onbrez Breezhaler
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N2O3
- CAS Number
- 312753-06-3
- Unique Ingredient Identifier
- 8OR09251MQ
- Background
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohal...
- Indication
For the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenances
ANTES B+ Clinical Trial
- Conditions
- Interventions
- Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30DDrug: BrimicaDrug: DuaklirDrug: UltibroDrug: UlunarDrug: XoternaDrug: AnoroDrug: LaventairDrug: Spiolto RespimatDrug: YanimoDrug: ForadilDrug: BroncoralDrug: Formoterol stadaDrug: OxisDrug: FormatrisDrug: Formoterol AldoDrug: OnbrezDrug: OslifDrug: HirobrizDrug: StriverdiDrug: BeglanDrug: BetamicanDrug: InaspirDrug: SereventDrug: SoltelDrug: EkliraDrug: BretarisDrug: SeebriDrug: TovanorDrug: EnurevDrug: SpirivaDrug: TavulusDrug: SirkavaDrug: BraltusDrug: GregalDrug: IncruseDrug: Rolufta
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fundacio Privada Mon Clinic Barcelona
- Target Recruit Count
- 1028
- Registration Number
- NCT06282861
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain
Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 97
- Registration Number
- NCT05506865
- Locations
- 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico
Drug Utilization Study for Olodaterol
- Conditions
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27606
- Registration Number
- NCT03030638
- Locations
- 🇫🇷
IMS Health Information solutions, Courbevoie, France
🇳🇱Pharmo Institute, Utrecht, Netherlands
🇩🇰Aarhus Universitetshospital Skejby, Aarhus, Denmark
Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 31
- Registration Number
- NCT02953041
- Locations
- 🇨🇦
Asthma Research Lab, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 42
- Registration Number
- NCT02872090
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire, Besançon, France
Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Centro Cardiologico Monzino
- Target Recruit Count
- 44
- Registration Number
- NCT02598505
- Locations
- 🇮🇹
Centro Cardiologico Monzino, Milano, MI, Italy
Pulmonary Gas Exchange Response to Indacaterol in COPD
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 20
- Registration Number
- NCT02547558
- Locations
- 🇪🇸
Hospital Clínic, Barcelona, Spain
Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-10-16
- Target Recruit Count
- 40
- Registration Number
- NCT02473237
- Locations
- 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
- Conditions
- Interventions
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02418468
- Locations
- 🇭🇰
Novartis Investigative Site, Hong Kong, Hong Kong
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 967
- Registration Number
- NCT02257385
- Locations
- 🇸🇰
GSK Investigational Site, Vrable, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.